This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.
11/26/14 6:00AM
Martin Shkreli, the ousted CEO of Retrophin, received $3 million from selling company stock but delayed disclosure for two months, a new SEC filing shows.
11/25/14 12:41PM
The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.
11/24/14 9:39AM
BioMarin is betting that its experience in securing approvals for "orphan-disease" drugs can help Prosensa win approval for drisapersen, an experimental treatment for Duchenne muscular dystrophy.
11/24/14 6:34AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
11/21/14 6:00AM
The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.
11/19/14 1:25PM
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
11/19/14 9:38AM
The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
11/18/14 6:02PM
Using stem cells to repair damaged hearts is a great story, but proof remains elusive.
11/18/14 10:16AM
The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.
11/15/14 10:01AM
Positive data presented Friday, particularly the statistically significant survival benefit favoring patients treated with rindopepimut, has Celldex planning -- cautiously -- for a conversation with the FDA about accelerated approval.
11/14/14 3:35PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
11/14/14 6:00AM
J&J is paying $35 million upfront to Geron for rights to the drug.
11/13/14 4:34PM
An analysis of results from Oxigene's phase II study of fosbretabulin plus Avastin in recurrent ovarian cancer.
11/12/14 5:12AM
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
11/10/14 10:40AM
A Dendreon agreement calls for a financial restructuring of the company in which the bondholders will receive equity for the debt owed, potentially wiping out current equity shareholders.
11/10/14 7:12AM
Based on promising results from a small study, Sage expects to start a larger phase III study of its anti-seizure drug next year.
11/10/14 12:11AM
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
11/9/14 6:23PM
A deeply flawed FDA advisory panel voted to support Rockwell's iron replacement therapy for dialysis. FDA still must decide if the product is approvable.
11/7/14 7:44AM
Salix Pharmaceuticals has been rocked by an accounting scandal involving inventory levels of its key gastrointestinal drugs, forcing the company to cut financial forecasts for the rest of the year.
11/6/14 7:33PM
The new clinical data on Bluebird's gene therapy are contained in a just-released abstract ahead of next month's American Society of Hematology annual meeting.
11/6/14 11:31AM
New results from a study of Epizyme's leukemia drug were disclosed ahead of next month's American Society of Hematology annual meeting.
11/6/14 11:12AM
The new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.
11/6/14 9:57AM
Aegerion Pharmaceuticals is spending $325 million, or almost all of its cash, to purchase a recently approved, orphan-disease drug from AstraZeneca.
11/6/14 7:55AM

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs